APA (7th ed.) Citation

Taylor, P., Blanco, R., Ikeda, K., Jia, B., Chen, Y., Walls, C., . . . Fautrel, B. (2021). Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Taylor, P., R. Blanco, K. Ikeda, B. Jia, YF Chen, C. Walls, E. Haladyj, and B. Fautrel. Baricitinib Provides Greater Improvements in Patient-reported Outcomes Across All Disease Activity Levels Compared to Placebo and Adalimumab in Rheumatoid Arthritis. BMJ Publishing Group, 2021.

MLA (9th ed.) Citation

Taylor, P., et al. Baricitinib Provides Greater Improvements in Patient-reported Outcomes Across All Disease Activity Levels Compared to Placebo and Adalimumab in Rheumatoid Arthritis. BMJ Publishing Group, 2021.